BioSpace News Archive

The global digital pregnancy kit market has witnessed significant traction in the past few years, with a massive shift in consumer preference towards innovative and technologically advanced products and vast technological advancements seen in these products key to the steady growth of the market.

Wilmington, Delaware, United States, Transparency Market Research Inc.: The global analgesic infusion pumps market is expected to expand at a healthy rate from 2021 to 2031.

An array of possibilities can cause vulvodynia, such as sjogren’s syndrome, infection, autoimmune disorder, allergy, genetic predisposition to inflammation, other sensitivities such as oxalates in the urine.

Neurological diseases have affected millions around the globe, and are known to be one of the worst kinds of maladies that can strike absolutely anyone.

Wilmington, Delaware, United States, Transparency Market Research Inc.: The global powered surgical instruments market is anticipated to grow at a favorable rate from 2021 to 2031.

Innate Pharma SA, announced that a planned futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca did not meet a pre-defined threshold for efficacy.

The AOP Health Group is a European pioneer for integrated therapies for rare diseases and in critical care headquartered in Vienna, Austria.

Capitalizing on Philadelphia’s emergence as a national hub for cell and gene therapy, SmartLabs, a Boston-based Laboratory-as-a-Service leader, announced plans to open its first facility in the city in addition to SmartLabs’ advanced resourcing in Boston and the Bay Area.

BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced that it will hold a conference call to update shareholders on financial results for the second quarter, ended on June 30, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time on Monday, August 15, 2022.

Nutriband Inc. announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for its patent application, CA 2937649, entitled “Abuse and Misuse Deterrent Transdermal Systems,” that protects its AVERSA™ transdermal abuse deterrent technology.